MS4322

Target: MS4322 selectively targets protein arginine methyltransferase 5, commonly abbreviated PRMT5.

Binding site: Its EPZ015666-derived ligand binds the PRMT5 catalytic methyltransferase active site.

Mechanism of action: MS4322, also known as YS43-22, is a first-in-class VHL-recruiting PRMT5 PROTAC degrader. It was designed by linking the PRMT5 inhibitor EPZ015666 to a VHL E3 ligase ligand, enabling induced proximity between PRMT5 and VHL-containing ubiquitination machinery. This interaction promotes PRMT5 ubiquitination and proteasome-mediated degradation while also suppressing PRMT5 methyltransferase activity. MS4322 is useful for studying PRMT5-dependent arginine methylation, chromatin regulation, tumor-cell growth dependence, degradation kinetics, and differences between enzymatic inhibition and removal of the PRMT5 protein complex.

• PROTAC-Driven Cancer Research: MS4322 facilitates the targeted degradation of oncogenic proteins, offering a powerful tool for cancer research. By selectively degrading specific proteins, researchers can study the effects of protein loss on cancer cell viability and identify potential therapeutic targets.

• Neurodegenerative Disease Models: Utilizing MS4322 in neurobiology research enables the targeted degradation of proteins implicated in neurodegenerative diseases. This approach aids in understanding disease mechanisms and evaluating the potential of protein degradation as a therapeutic strategy.

• Drug Resistance Studies: MS4322 is instrumental in investigating mechanisms of drug resistance. Through targeted protein degradation, researchers can dismantle resistance pathways by eliminating key proteins, paving the way for developing more effective treatment regimens.

• Signal Transduction Pathway Analysis: By employing MS4322, scientists can dissect complex signaling networks through targeted degradation of specific pathway components. This approach enhances the understanding of cellular signaling dynamics and identifies critical nodes for therapeutic intervention.